Central Nervous System (CNS) Biomarker Market Size, Share, Growth, Analysis and Forecast 2023-2030

The global CNS biomarkers market is anticipated to grow at a considerable CAGR of 15.5% during the forecast period. The key companies across the globe are adopting different business strategies including expanding their geographic presence, R&D activities, new product approvals, mergers & acquisitions, partnerships, and collaborations to increase market share. For instance, in September 20210, Siemens AG has announced the collaboration with Novartis AG to develop and commercialize diagnostic tests for therapeutic products across Novartis' therapeutic pipeline. The initial program assists Novartis' MS and other neuroscience programs by supporting the development of a serum neurofilament light chain (NFL) immunoassay. NFL is a highly specific biomarker for nerve cell injury that may be found in both the CSF and the blood. NFL levels in the blood have been linked to disease activity and disability outcomes in a variety of major neurological disorders, including MS.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/central-nervous-system-cns-biomarkers-market

Further, in April 2018, Novartis AG announced that it has merged with AveXis, Inc., a Nasdaq-listed clinical-stage gene therapy company based in the US, for an estimated $8.7 billion. AveXis has the region's AAV9 gene therapy production capabilities as well as substantial R&D skills, which include pipeline products for Rett Syndrome (RTT) and a hereditary variant of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene, in addition to AVXS-101. AAV9 is a clinically established gene delivery method for diseases of the CNS. Besides, in May 2018, AstraZeneca Plc and Luye Pharma Group, Ltd. (Luye Pharma) have agreed on the sale and license of Seroquel and Seroquel XR in the UK, China, Brazil, Australia, Saudi Arabia, Mexico, and South Korea, among others. AstraZeneca's aim to focus on its three core therapy areas of Oncology, Cardiovascular, Renal & Metabolism, and Respiratory is mentioned in this agreement. Thus, the collaborations and agreement among major players for the enhancement in the treatment of CNS are to propel the market growth during the forecast period.

Market Coverage

The market number available for - 2020-2027
Base year- 2020
Forecast period- 2021-2027
Segment Covered-
o By Application

o By Type

o By End-User

Regions Covered-
o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape- Eli Lilly & Co., Bio-Rad Laboratories, Inc., F. Hoffman-La Roche Ltd., Thermo Fisher Scientific, Inc., Biogen Inc., Novartis AG, Fujirebio, Pfizer Inc., and Banyan Biomarkers, Inc., among others

Key questions addressed by the report

What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global CNS Biomarkers Market Report Segment

By Application

Drug Discovery & Development
Personalized Medicine
Disease Risk Assessment
Other

By Type

Safety Biomarker
Efficacy Biomarker
Predictive Biomarker
Prognostic Biomarker
Validation Biomarker

By End-User

Diagnostic Labs
Hospitals & Clinics
Research Centers

A full report of Central Nervous System (CNS) Biomarker Market is available at: https://www.omrglobal.com/industry-reports/central-nervous-system-cns-biomarkers-market

Central Nervous System (CNS) Biomarker Market- Segment by Region

North America

United States
Canada

Europe

Germany
United Kingdom
France
Spain
Italy
Rest of Europe

Asia-Pacific

China
Japan
India
Rest of Asia-Pacific

Rest of the World

Middle East & Africa
Latin America

Company Profiles

AbbVie Inc
Adlyfe Inc.
ADxNeuroSciences NV
Altoida, Inc.
Aposense Ltd.
Applied NeuroSolutions, Inc.
AstraZeneca Plc
Avacta Group PLC
Biogen Inc.
Fujirebio Diagnostics, Inc. (Innogenetics)
GlaxoSmithKline plc
Iron Horse Diagnostics, Inc.
Johnson & Johnson Services, Inc.
Merck KGaA
Metabolon, Inc.

Reasons to Buying From us -

We cover more than 15 major industries, further segmented into more than 90 sectors.
More than 120 countries are for analysis.
Over 100+ paid data sources mined for investigation.
Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.